PortalPublikationenCarfilzomib, dexamethasone and daratumumab in relapsed or re...

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Standard

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. / Quach, Hang; Nooka, Ajay; Samoylova, Olga; Venner, Christopher P; Kim, Kihyun; Facon, Thierry; Spencer, Andrew; Usmani, Saad Z; Grosicki, Sebastian; Suzuki, Kenshi; Delimpasi, Sosana; Weisel, Katja; Obreja, Mihaela; Zahlten-Kumeli, Anita; Mateos, Maria-Victoria.

in: BRIT J HAEMATOL, Jahrgang 194, Nr. 4, 08.2021, S. 784-788.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Quach, H, Nooka, A, Samoylova, O, Venner, CP, Kim, K, Facon, T, Spencer, A, Usmani, SZ, Grosicki, S, Suzuki, K, Delimpasi, S, Weisel, K, Obreja, M, Zahlten-Kumeli, A & Mateos, M-V 2021, 'Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy', BRIT J HAEMATOL, Jg. 194, Nr. 4, S. 784-788. https://doi.org/10.1111/bjh.17541

APA

Quach, H., Nooka, A., Samoylova, O., Venner, C. P., Kim, K., Facon, T., Spencer, A., Usmani, S. Z., Grosicki, S., Suzuki, K., Delimpasi, S., Weisel, K., Obreja, M., Zahlten-Kumeli, A., & Mateos, M-V. (2021). Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. BRIT J HAEMATOL, 194(4), 784-788. https://doi.org/10.1111/bjh.17541

Vancouver

Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T et al. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. BRIT J HAEMATOL. 2021 Aug;194(4):784-788. https://doi.org/10.1111/bjh.17541

Bibtex

@article{fde8e0e4c21e40e2963ab9aa9b8c13ec,
title = "Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy",
author = "Hang Quach and Ajay Nooka and Olga Samoylova and Venner, {Christopher P} and Kihyun Kim and Thierry Facon and Andrew Spencer and Usmani, {Saad Z} and Sebastian Grosicki and Kenshi Suzuki and Sosana Delimpasi and Katja Weisel and Mihaela Obreja and Anita Zahlten-Kumeli and Maria-Victoria Mateos",
year = "2021",
month = aug,
doi = "10.1111/bjh.17541",
language = "English",
volume = "194",
pages = "784--788",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

AU - Quach, Hang

AU - Nooka, Ajay

AU - Samoylova, Olga

AU - Venner, Christopher P

AU - Kim, Kihyun

AU - Facon, Thierry

AU - Spencer, Andrew

AU - Usmani, Saad Z

AU - Grosicki, Sebastian

AU - Suzuki, Kenshi

AU - Delimpasi, Sosana

AU - Weisel, Katja

AU - Obreja, Mihaela

AU - Zahlten-Kumeli, Anita

AU - Mateos, Maria-Victoria

PY - 2021/8

Y1 - 2021/8

U2 - 10.1111/bjh.17541

DO - 10.1111/bjh.17541

M3 - Other (editorial matter etc.)

C2 - 34046887

VL - 194

SP - 784

EP - 788

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 4

ER -